Apexigen Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 31

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.7M

Apexigen General Information

Description

Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer.. The company's pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in clinical development, and also includes several preclinical stage immune-oncology programs.

Contact Information

Website
www.apexigen.com
Formerly Known As
Apex Biotherapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 900 Industrial Road
  • Suite C
  • San Carlos, CA 94070
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Pyxis Oncology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 900 Industrial Road
  • Suite C
  • San Carlos, CA 94070
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apexigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 23-Aug-2023 $10.7M Completed Generating Revenue
7. PIPE 24-Jan-2023 Completed Generating Revenue
6. PIPE 01-Aug-2022 Completed Generating Revenue
5. Reverse Merger 01-Aug-2022 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 24-Mar-2020 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 08-Aug-2018 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series B) 22-Jul-2016 $15M $35M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A1) 08-Aug-2013 $20M $20M Completed Startup
To view Apexigen’s complete valuation and funding history, request access »

Apexigen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A2 12,652,762 $0.001000 $0.02 $0.2 $0.2 1x $0.2 6.69%
Series A1 39,196,116 $0.001000 $0.04 $0.51 $0.51 1x $0.51 20.73%
To view Apexigen’s complete cap table history, request access »

Apexigen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of ant
Drug Discovery
San Carlos, CA
31 As of 2023

South San Francisco, CA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apexigen Competitors (99)

One of Apexigen’s 99 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Aileron Therapeutics Formerly VC-backed Watertown, MA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Theolytics Venture Capital-Backed Oxford, United Kingdom
You’re viewing 5 of 99 competitors. Get the full list »

Apexigen Patents

  • 101

    Total Documents Applications and Grants

  • Total Patents Families

  • 55

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Apexigen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4384276-A1 Biomarkers for cd40 agonist therapy Pending 10-Aug-2021
US-20240336693-A1 Biomarkers for cd40 agonist therapy Pending 10-Aug-2021
EP-4110819-A1 Anti-sirpa antibodies and methods of use Inactive 28-Feb-2020
US-20230340112-A1 Anti-sirpa antibodies and methods of use Pending 28-Feb-2020
EP-4031177-A2 Anti-tnfr2 antibodies and methods of use Pending 17-Sep-2019 C07K16/2878
To view Apexigen’s complete patent history, request access »

Apexigen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apexigen Former Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
3E Bioventures (China) Venture Capital Minority
AimTop Ventures Venture Capital Minority
Amkey Ventures Venture Capital Minority
Brightway Future Capital Venture Capital Minority
Brookline Capital Acquisition Special Purpose Acquisition Company (SPAC) Minority
You’re viewing 5 of 24 investors. Get the full list »

Apexigen Acquisitions (1)

Apexigen’s most recent deal was a Merger/Acquisition with Brookline Capital Acquisition. The deal was made on 01-Aug-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Brookline Capital Acquisition 01-Aug-2022 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Apexigen’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Apexigen FAQs

  • When was Apexigen founded?

    Apexigen was founded in 2010.

  • Where is Apexigen headquartered?

    Apexigen is headquartered in San Carlos, CA.

  • What is the size of Apexigen?

    Apexigen has 31 total employees.

  • What industry is Apexigen in?

    Apexigen’s primary industry is Drug Discovery.

  • Is Apexigen a private or public company?

    Apexigen is a Private company.

  • What is the current valuation of Apexigen?

    The current valuation of Apexigen is .

  • What is Apexigen’s current revenue?

    The current revenue for Apexigen is .

  • How much funding has Apexigen raised over time?

    Apexigen has raised $176M.

  • Who are Apexigen’s investors?

    3E Bioventures (China), AimTop Ventures, Amkey Ventures, Brightway Future Capital, and Brookline Capital Acquisition are 5 of 24 investors who have invested in Apexigen.

  • Who are Apexigen’s competitors?

    CytomX Therapeutics, Sorrento Therapeutics, Aileron Therapeutics, CRISPR Therapeutics, and Theolytics are some of the 99 competitors of Apexigen.

  • When was Apexigen acquired?

    Apexigen was acquired on 23-Aug-2023.

  • Who acquired Apexigen?

    Apexigen was acquired by Pyxis Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »